You are not logged in.

β-blockers reduce bone resorption marker in early postmenopausal women

Pasco, Julie A., Henry, Margaret J., Nicholson, Geoffrey C., Schneider, Hans G. and Kotowicz, Mark A. 2005, β-blockers reduce bone resorption marker in early postmenopausal women, Annals of human biology, vol. 32, no. 6, pp. 738-745, doi: 10.1080/03014460500292168.

Attached Files
Name Description MIMEType Size Downloads

Title β-blockers reduce bone resorption marker in early postmenopausal women
Alternative title Beta-blockers reduce bone resorption marker in early postmenopausal women
Author(s) Pasco, Julie A.ORCID iD for Pasco, Julie A.
Henry, Margaret J.
Nicholson, Geoffrey C.
Schneider, Hans G.
Kotowicz, Mark A.ORCID iD for Kotowicz, Mark A.
Journal name Annals of human biology
Volume number 32
Issue number 6
Start page 738
End page 745
Total pages 8
Publisher Informa Healthcare
Place of publication Abingdon, England
Publication date 2005
ISSN 0301-4460
Keyword(s) Beta-blocker
bone turnover markers
bone loss
population studies
ostmenopausal women
Summary Background: There is evidence to suggest that β-blockers used in the management of cardiovascular disease may also modulate bone metabolism and reduce bone fragility.

Aim: The study aimed to determine the association between β-blocker use, serum markers of bone turnover and bone loss in early postmenopausal women.

Subjects and methods: In this observational study, we evaluated β-blocker exposure in association with serum levels of C-telopeptide and bone-specific alkaline phosphatase, and rates of bone loss. β-blocker use, concomitant therapy and lifestyle were documented for 197 women (50–59 years), 175 of whom had changes in whole body bone mineral density monitored over a 2–year period.

Results: Twenty-four β-blocker users were identified at baseline. After controlling for concomitant use of hormone therapy, C-telopeptide levels were 6.7% lower among β-blocker users (p = 0.02). No association was detected between bone-specific alkaline phosphatase and β-blocker use. Analysis of 15 β-blocker users and 152 non-users identified 2 years post-baseline showed that levels of C-telopeptide but not bone-specific alkaline phosphatase were predictors of adjusted rates of bone loss (p = 0.008 and p>0.05, respectively). Adjusted rates of bone loss were −0.001 ± 0.026 g cm−2 over 2 years for the users and −0.004 ± 0.025 g cm−2 over 2 years for non-users, but this difference was not significant.

Conclusion: β-blockers might suppress bone resorption with relative preservation of bone formation. A study with greater power is required to determine whether β-blocker use is associated with lower rates of bone loss.
Language eng
DOI 10.1080/03014460500292168
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2005, Taylor & Francis
Persistent URL

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 15 times in TR Web of Science
Scopus Citation Count Cited 15 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 239 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Thu, 01 Mar 2012, 10:34:39 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact